These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

283 related articles for article (PubMed ID: 29146695)

  • 1. First-in-Human Human Epidermal Growth Factor Receptor 2-Targeted Imaging Using
    Ulaner GA; Lyashchenko SK; Riedl C; Ruan S; Zanzonico PB; Lake D; Jhaveri K; Zeglis B; Lewis JS; O'Donoghue JA
    J Nucl Med; 2018 Jun; 59(6):900-906. PubMed ID: 29146695
    [TBL] [Abstract][Full Text] [Related]  

  • 2. First-in-Human Evaluation of Site-Specifically Labeled
    Yeh R; O'Donoghue JA; Jayaprakasam VS; Mauguen A; Min R; Park S; Brockway JP; Bromberg JF; Zhi WI; Robson ME; Sanford R; Modi S; Agnew BJ; Lyashchenko SK; Lewis JS; Ulaner GA; Zeglis BM
    J Nucl Med; 2024 Mar; 65(3):386-393. PubMed ID: 38272704
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of HER2-Positive Metastases in Patients with HER2-Negative Primary Breast Cancer by Using HER2-targeted
    Ulaner GA; Carrasquillo JA; Riedl CC; Yeh R; Hatzoglou V; Ross DS; Jhaveri K; Chandarlapaty S; Hyman DM; Zeglis BM; Lyashchenko SK; Lewis JS
    Radiology; 2020 Aug; 296(2):370-378. PubMed ID: 32515679
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 89Zr-Trastuzumab PET/CT for Detection of Human Epidermal Growth Factor Receptor 2-Positive Metastases in Patients With Human Epidermal Growth Factor Receptor 2-Negative Primary Breast Cancer.
    Ulaner GA; Hyman DM; Lyashchenko SK; Lewis JS; Carrasquillo JA
    Clin Nucl Med; 2017 Dec; 42(12):912-917. PubMed ID: 28872549
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Detection of HER2-Positive Metastases in Patients with HER2-Negative Primary Breast Cancer Using 89Zr-Trastuzumab PET/CT.
    Ulaner GA; Hyman DM; Ross DS; Corben A; Chandarlapaty S; Goldfarb S; McArthur H; Erinjeri JP; Solomon SB; Kolb H; Lyashchenko SK; Lewis JS; Carrasquillo JA
    J Nucl Med; 2016 Oct; 57(10):1523-1528. PubMed ID: 27151988
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase I Study of 68Ga-HER2-Nanobody for PET/CT Assessment of HER2 Expression in Breast Carcinoma.
    Keyaerts M; Xavier C; Heemskerk J; Devoogdt N; Everaert H; Ackaert C; Vanhoeij M; Duhoux FP; Gevaert T; Simon P; Schallier D; Fontaine C; Vaneycken I; Vanhove C; De Greve J; Lamote J; Caveliers V; Lahoutte T
    J Nucl Med; 2016 Jan; 57(1):27-33. PubMed ID: 26449837
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Imaging of HER2 with [
    Massicano AVF; Lee S; Crenshaw BK; Aweda TA; El Sayed R; Super I; Bose R; Marquez-Nostra BV; Lapi SE
    Cancer Biother Radiopharm; 2019 May; 34(4):209-217. PubMed ID: 30676778
    [No Abstract]   [Full Text] [Related]  

  • 8. [
    Laforest R; Lapi SE; Oyama R; Bose R; Tabchy A; Marquez-Nostra BV; Burkemper J; Wright BD; Frye J; Frye S; Siegel BA; Dehdashti F
    Mol Imaging Biol; 2016 Dec; 18(6):952-959. PubMed ID: 27146421
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [
    Lu Y; Li M; Massicano AVF; Song PN; Mansur A; Heinzman KA; Larimer BM; Lapi SE; Sorace AG
    Molecules; 2021 Mar; 26(6):. PubMed ID: 33809310
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics, Biodistribution, and Radiation Dosimetry for
    O'Donoghue JA; Lewis JS; Pandit-Taskar N; Fleming SE; Schöder H; Larson SM; Beylergil V; Ruan S; Lyashchenko SK; Zanzonico PB; Weber WA; Carrasquillo JA; Janjigian YY
    J Nucl Med; 2018 Jan; 59(1):161-166. PubMed ID: 28637800
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biodistribution of 89Zr-trastuzumab and PET imaging of HER2-positive lesions in patients with metastatic breast cancer.
    Dijkers EC; Oude Munnink TH; Kosterink JG; Brouwers AH; Jager PL; de Jong JR; van Dongen GA; Schröder CP; Lub-de Hooge MN; de Vries EG
    Clin Pharmacol Ther; 2010 May; 87(5):586-92. PubMed ID: 20357763
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase I study to assess safety, biodistribution and radiation dosimetry for
    Merkx RIJ; Lobeek D; Konijnenberg M; Jiménez-Franco LD; Kluge A; Oosterwijk E; Mulders PFA; Rijpkema M
    Eur J Nucl Med Mol Imaging; 2021 Sep; 48(10):3277-3285. PubMed ID: 33651116
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of PET/CT imaging with [89Zr]Zr-DFO-girentuximab: a phase 1 clinical study in Japanese patients with renal cell carcinoma (Zirdac-JP).
    Nakaigawa N; Hasumi H; Utsunomiya D; Yoshida K; Ishiwata Y; Oka T; Hayward C; Makiyama K
    Jpn J Clin Oncol; 2024 Aug; 54(8):873-879. PubMed ID: 38864246
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biodistribution and Radiation Dosimetry of the Anti-HER2 Affibody Molecule 68Ga-ABY-025 in Breast Cancer Patients.
    Sandström M; Lindskog K; Velikyan I; Wennborg A; Feldwisch J; Sandberg D; Tolmachev V; Orlova A; Sörensen J; Carlsson J; Lindman H; Lubberink M
    J Nucl Med; 2016 Jun; 57(6):867-71. PubMed ID: 26912439
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Functional imaging of human epidermal growth factor receptor 2-positive metastatic breast cancer using (64)Cu-DOTA-trastuzumab PET.
    Mortimer JE; Bading JR; Colcher DM; Conti PS; Frankel PH; Carroll MI; Tong S; Poku E; Miles JK; Shively JE; Raubitschek AA
    J Nucl Med; 2014 Jan; 55(1):23-9. PubMed ID: 24337604
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of (89)Zr-pertuzumab in Breast cancer xenografts.
    Marquez BV; Ikotun OF; Zheleznyak A; Wright B; Hari-Raj A; Pierce RA; Lapi SE
    Mol Pharm; 2014 Nov; 11(11):3988-95. PubMed ID: 25058168
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase I Trial of
    D'Huyvetter M; Vos J; Caveliers V; Vaneycken I; Heemskerk J; Duhoux FP; Fontaine C; Vanhoeij M; Windhorst AD; Aa FV; Hendrikse NH; Eersels JLE; Everaert H; Gykiere P; Devoogdt N; Raes G; Lahoutte T; Keyaerts M
    J Nucl Med; 2021 Aug; 62(8):1097-1105. PubMed ID: 33277400
    [No Abstract]   [Full Text] [Related]  

  • 18. Zirconium-89 labeled panitumumab: a potential immuno-PET probe for HER1-expressing carcinomas.
    Bhattacharyya S; Kurdziel K; Wei L; Riffle L; Kaur G; Hill GC; Jacobs PM; Tatum JL; Doroshow JH; Kalen JD
    Nucl Med Biol; 2013 May; 40(4):451-7. PubMed ID: 23454247
    [TBL] [Abstract][Full Text] [Related]  

  • 19. First-in-human molecular imaging of HER2 expression in breast cancer metastases using the 111In-ABY-025 affibody molecule.
    Sörensen J; Sandberg D; Sandström M; Wennborg A; Feldwisch J; Tolmachev V; Åström G; Lubberink M; Garske-Román U; Carlsson J; Lindman H
    J Nucl Med; 2014 May; 55(5):730-5. PubMed ID: 24665085
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Imaging with [
    Tendler S; Dunphy MP; Agee M; O'Donoghue J; Aly RG; Choudhury NJ; Kesner A; Kirov A; Mauguen A; Baine MK; Schoder H; Weber WA; Rekhtman N; Lyashchenko SK; Bodei L; Morris MJ; Lewis JS; Rudin CM; Poirier JT
    Lancet Oncol; 2024 Aug; 25(8):1015-1024. PubMed ID: 38950555
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.